Proposals related to drug pricing, including the Administrations Most-Favored-Nation Prescription Drug Pricing proposal, to include CMMIs GUARD and GLOBE models, implementation of drug-related provisions of the Inflation Reduction Act, and administration of the 340B Drug Pricing Program. PBM reform proposals. The Help Ensure Lower Patient (HELP) Copays Act. Intellectual property proposals relating to life sciences. S.1930/HR 3731, Small Biotech Innovation Act. Health agency funding levels. Development and implementation of national security policies impacting biotechnology, including regulatory frameworks that may affect cross-border investments, research collaborations, and business operations
Source-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- Not reported
- Expenses
- $560,000.00
- Registrant
- EXELIXIS INC.
- Client
- EXELIXIS INC.
- Filing UUID
- 6388687f-7f28-445e-b77d-8c49c379daa2
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Federal tax policy issues affecting the biopharmaceutical industry, including provisions related to business taxation, research and development incentives, and broader fiscal legislation.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.